New additions strengthen Quidel's management team
This article was originally published in Clinica
Point-of-care diagnostics firm Quidel has appointed several executives to its management team: Tim Stenzel as chief scientific officer; Larry Mimms as vice-president of R&D; and Ratan Borkar as vice-president of business development. They join Judi Tilghman, who was appointed vice-president of technology assessment in July. Dr Stenzel, who was previously vice-president and chief medical officer of molecular diagnostics company Asuragen, will be responsible for technology assessment and implementing Quidel's molecular diagnostics strategy. Dr Mimms most recently headed his own company, VDx Laboratories, and has also held a number of senior positions with Gen-Probe. Mr Borkar was previously an investment banker for JP Morgan, while Dr Tilghman has worked for EMD Chemicals, Luminex and Sigma Aldrich in strategic planning and business development roles.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.